{"id":"buprenorphine-otp","safety":{"commonSideEffects":[{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Constipation"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Insomnia"},{"rate":null,"effect":"Sweating"},{"rate":null,"effect":"Respiratory depression"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Buprenorphine binds with high affinity to mu-opioid receptors in the central nervous system, producing partial agonist effects that reduce withdrawal symptoms and cravings while having a lower abuse potential than full opioid agonists. When combined with OTP (opioid treatment program), it is delivered as part of a comprehensive medication-assisted treatment (MAT) regimen that includes counseling and psychosocial support to address opioid use disorder.","oneSentence":"Buprenorphine is a partial mu-opioid receptor agonist combined with opioid treatment program (OTP) services to reduce opioid use disorder symptoms and cravings.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:41:58.216Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Opioid use disorder (maintenance treatment)"},{"name":"Opioid dependence"}]},"trialDetails":[{"nctId":"NCT07214389","phase":"NA","title":"PRoducing Outcome Measures for OTP Quality Improvement","status":"NOT_YET_RECRUITING","sponsor":"RTI International","startDate":"2025-10-03","conditions":"Opioid Use Disorder","enrollment":4500},{"nctId":"NCT04309565","phase":"NA","title":"Transitions Clinic Network: Post Incarceration Addiction Treatment, Healthcare, and Social Support","status":"ACTIVE_NOT_RECRUITING","sponsor":"Yale University","startDate":"2021-04-21","conditions":"Opioid Addiction","enrollment":400},{"nctId":"NCT03544112","phase":"","title":"Emergency Department Connection to Care With Buprenorphine for Opioid Use Disorder","status":"COMPLETED","sponsor":"NYU Langone Health","startDate":"2018-06-11","conditions":"Opioid-use Disorder","enrollment":390},{"nctId":"NCT00574067","phase":"PHASE3","title":"Buprenorphine for Prisoners","status":"COMPLETED","sponsor":"Friends Research Institute, Inc.","startDate":"2008-09","conditions":"Heroin Addiction","enrollment":213}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":60,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Suboxone"],"phase":"phase_3","status":"active","brandName":"Buprenorphine +OTP","genericName":"Buprenorphine +OTP","companyName":"Friends Research Institute, Inc.","companyId":"friends-research-institute-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Buprenorphine is a partial mu-opioid receptor agonist combined with opioid treatment program (OTP) services to reduce opioid use disorder symptoms and cravings. Used for Opioid use disorder (maintenance treatment), Opioid dependence.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}